Singletto logo

Singletto

singletto.com

Singletto develops and licenses Oxafence Active Protection, a materials-applied antimicrobial technology designed to integrate into existing products and manufacturing processes. Its platform enables ongoing antimicrobial performance within materials for healthcare, military, industry, and consumer applications, addressing environments where microbial exposure accumulates. The organization aims to unlock new capabilities in antimicrobial materials by partnering with manufacturers and researchers.

Facts

HQ
Seattle, US
Sectors
Biotechnology
Founded
2020
Type
Corporation Seattle business license
Employees
10
Registered name
Singletto Inc Seattle business license
Stage
Series A
Members see funding amounts.
.
Founders
James (Jim) Chen, MD, Thomas (Tom) Lendvay, MD

Is this your organization? Claim it

Seattle Startup Singletto Launches FDA-Approved Virus-Killing Masks on Amazon Following $10M Funding and DARPA Support

Seattle startup Singletto, with $10 million in funding and support from DARPA, has launched FDA-approved virus-neutralizing face masks on Amazon using its Oxafence Active Protection technology that kills 99.9% of certain viruses. The masks are the only FDA-cleared products in the U.S. that inactivate tested viruses and may have applications in healthcare and national security.

People

  • John Bjornson
    John Bjornson Executive Officer, Director, Co-Founder and Chief Executive Officer
  • Thomas Lendvay
    Thomas Lendvay Executive Officer, Director, Co-Founder and Chief Medical Officer
  • James Chen Executive, Chief Scientific Officer

Online